Homepage Top Section2

Ackermans & van Haaren spearheaded the investment round, with participation from both new investors including Driehaus Capital Management and Quest for Growth. Current investors namely BioGeneration Ventures, Capricorn

AbbVie Ventures led the investment round and, as part of its commitment, the company’s associate director Danjuma Quarless will join the board of directors of Oisín. As part

The designation comes after the FDA reviewed the available initial clinical data showing AIC100’s potential to treat recurrent ATC. RMAT designation is aimed at expediting the development and

A subsidiary of Bayer, the company aims to enhance its chemoproteomics screening capacity and further its clinical and preclinical programmes with this new facility. The centre will also

This alliance is aimed at transforming scientific breakthroughs at Oxford into potential new treatments. Under the deal, Apollo will detect and evaluate established therapeutic targets from Oxford’s biomedical

This designation aims to expedite the development and review of the therapy for paediatric patients with early-stage type 1 diabetes carrying the HLA DR3-DQ2 genotype. The status aids

Champion VC and LRM founder and CEO Dr Samuel Lynch spearheaded the financing round. This funding will support the company’s efforts to leverage its patented pure platelet-derived growth

The new line, representing an investment of nearly €6.6m ($7.1m), is located at the Life Science Center in Nantong. This development is aimed at meeting the increasing local

SPS is a rare, debilitating neurological autoimmune disorder characterised by muscle stiffness and spasms. Kyverna’s KYV-101 is an autologous, fully human CD19 CAR T-cell therapy designed to address